Notice of Proposed Sale · 144
Regencell Bioscience Holdings Limited
RGCNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Regencell Bioscience Holdings Ltd
- Issuer CIK
- 0001829667
- SEC file number
- 001-40617
- Phone
- 852-2155-0823
- Person for whose account securities are to be sold
- WING YAN WILLIAM LO
- Relationships to issuer
- Director
- Street
- 9/F Chinachem Leighton Plaza
- Street (continued)
- 29 Leighton Road
- City
- Causeway Bay
- State / country code
- K3
- Postal code
- HK
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Ordinary shares, par value $0.00001 | 36,001 | 169,924.72 | 495,884,376 | 11/18/2026 | Nasdaq | Platinum Broking Company Limited |
Broker / market maker — proposed row 1, entry 1
- Name
- Platinum Broking Company Limited
- Street
- 21/F LHT Tower
- Street (continued)
- 31 Queen's Road Central
- City
- Hong Kong
- State / country code
- K3
- Postal code
- HK
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Ordinary shares, par value $0.00001 | 11/17/2026 | Exercise of stock options under the Issuer's share option plan | The Issuer | 36,001 | N | 11/17/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The aggregate market value of the ordinary shares proposed to be sold is based on the closing market price of US$4.72 per ordinary share on November 16, 2026. The number of ordinary shares outstanding reflects the Issuer's number of ordinary shares issued and outstanding as of October 7, 2026, as disclosed in the Issuer's annual report on Form 20-F for the fiscal year ended June 30, 2026 filed with the U.S. Securities and Exchange Commission (the "Commission") on October 7, 2026. In Table I, the acquisition transaction is pursuant to the exercise of stock options granted to the director named in this Form by the Issuer under the Issuer's 2021 share option plan and pursuant to the Issuer's currently effective Form S-8 registration statement (file no. 333-300083) filed with the Commission on November 16, 2026.
Notice signature
- Notice date
- 11/17/2026
- Signed
- /s/ WING YAN WILLIAM LO
Company context
We are an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Our goal is to save and improve the lives of the patients, their families and caregivers and become a market leader for natural and holistic treatments for neurological disorders globally.